Pliant Therapeutics
PLRX
134 hedge funds and large institutions have $1.14B invested in Pliant Therapeutics in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 53 increasing their positions, 34 reducing their positions, and 20 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 34
10% more capital invested
Capital invested by funds: $1.04B → $1.14B (+$100M)
4.82% more ownership
Funds ownership: 100.55% → 105.37% (+4.8%)
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
1% less funds holding
Funds holding: 136 → 134 (-2)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
65% less call options, than puts
Call options by funds: $2.06M | Put options by funds: $5.88M
Top Buyers
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$45.7M |
| 2 |
Morgan Stanley
New York
|
+$10.9M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$10M |
| 4 |
BlackRock
New York
|
+$7.28M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.61M |
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.31M |
| 2 |
First Manhattan
New York
|
-$6.42M |
| 3 |
VA
VR Adviser
New York
|
-$5.01M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$4.75M |
| 5 |
Millennium Management
New York
|
-$3.15M |
PLRX Hedge Fund Activity: Q4 2023 in Review
134 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q4 2023, worth a combined $1.14B — up 9.6% from $1.04B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of PLRX and 19 opened new positions — a net loss of 1 holder — while 34 trimmed existing stakes and 53 added.
The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $45.7M. The largest seller was RA Capital Management, cutting an estimated $7.31M.
- 134 institutional investors held Pliant Therapeutics (PLRX) as of Q4 2023, down from 136 in Q3 2023.
- Funds reported $1.14B of Pliant Therapeutics stock for Q4 2023, up 9.6% quarter-over-quarter.
- 19 funds opened new Pliant Therapeutics positions in Q4 2023 and 20 closed out, a net change of -1 holder.
- The largest Pliant Therapeutics buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $45.7M added.
- The largest Pliant Therapeutics seller in Q4 2023 was RA Capital Management, an estimated $7.31M sold.
Based on aggregated 13F filings for Q4 2023.